Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report
- First Online:
- Cite this article as:
- Greene, D.P., Ferriss, J.S. & Jazaeri, A.A. Cancer Chemother Pharmacol (2010) 66: 265. doi:10.1007/s00280-009-1159-6
- 119 Views
Platinum-based therapy is the cornerstone of ovarian cancer treatment. Development of platinum hypersensitivity can limit therapeutic options. In this brief report, we present case of successful cisplatin administration following two unsuccessful carboplatin desensitization attempts, and without the need for pre-treatment steroids.
Retrospective chart review was performed.
One case of recurrent primary peritoneal carcinoma previously treated with a carboplatin-based regimen, developed a platinum hypersensitivity. Two attempts at carboplatin desensitization were unsuccessful. Cisplatin was substituted and the patient achieved a complete response to therapy without further hypersensitivity.
Platinum-based therapies are vital to the treatment of primary peritoneal and ovarian carcinoma. Protocols that successfully incorporate platinum agents, despite a platinum hypersensitivity, are clinically relevant.